This site is intended for Healthcare Professionals only

Incorrect username and/or password, please try again or click to reset.

Tredaptive modified-release tablets - withdrawn throughout the European Union

2014-12-17 14:58:37 (11 year(s) ago)

Summary

(Merck Sharp & Dohme Ltd) Study showed failure to reduce major vascular events and increase in non-fatal serious adverse events – class 2 action within 48 hours. (EL (13)A/02)

Read full MHRA article

Respond to this alert

Sign up for your FREE ticket to see PharmData at the Pharmacy Show to see our latest products and features demonstrated live!